Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Size, Share, Regional Growth, 2026-2034

Market Overview

According to Fortune Business Insights, the global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market size was valued at USD 1,115.5 million in 2018. The market is projected to grow to USD 2,312.0 million by 2032, exhibiting a CAGR of 5.8% during the forecast period. North America dominated the alpha-1 antitrypsin deficiency augmentation therapy market with a market share of 55.58% in 2018.

Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market, 2018-2032.”

The analysis shows that companies are investing more in AATD therapies because of improved diagnostic techniques and the rising prevalence of the condition. For example, according to Kamada Ltd., there are around 100,000 people in the U.S. living with AATD, many of whom are undiagnosed. This trend indicates a strong and growing demand for augmentation therapy worldwide.

Major Players Profiled in the Market Report:

• Grifols, S.A.

• Kamada Ltd

• Shire plc (Baxalta)

• CSL Limited

Segments

Prolastin C to Dominate by Product Type

Based on product type, the market is divided into brands such as Prolastin C, Glassia, Aralast NP, and Zemaira/Respreeza. The Prolastin C segment holds the largest market share and dominates the market owing to patient-centric support programs like AlfaCare and the strong distribution networks of its manufacturer, Grifols, S.A.

Hospitals to Lead as Primary End-User

By end-user, the market is categorized into hospitals, specialty clinics, and others. The hospitals segment is leading the market due to the emergence of multispecialty care in developing economies and rising public and private investment in the healthcare sector.

Report Coverage

The report offers:

• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.

• Comprehensive insights into regional developments.

• List of major industry players.

• Key strategies adopted by the market players.

• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Source: https://www.fortunebusinessinsights.com/industry-reports/aatd-augmentation-therapy-market-100169

Drivers & Restraints

Improved Diagnostics and Awareness to Propel Market Growth

The rapid growth in the market is driven by improved diagnostic techniques for genetic disorders, coupled with the rising prevalence of AATD. As awareness and screening improve, more patients are correctly diagnosed, boosting the demand for augmentation therapy. Furthermore, the efficient distribution networks of leading manufacturers are helping to propel market growth at a remarkable rate.

However, the fact that the disease is often undiagnosed may hamper market growth. Since AATD symptoms can be similar to other respiratory conditions, many individuals remain undiagnosed or misdiagnosed, which limits the addressable patient population and restricts the market’s full potential.

Regional Insights

High Prevalence and Strong Company Presence Propel Market Growth in North America

North America holds the dominant AATD augmentation therapy market share and is projected to remain the leader during the forecast period. The region’s growth is attributed to the high prevalence of the disease in the U.S. and Canada, established diagnostic infrastructure, and the strategic presence of key manufacturing companies.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to increasing government participation in the prevention and control of genetic disorders and significant improvements in diagnostic techniques for critical diseases.

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market Future Growth:

The AATD augmentation therapy market is experiencing steady growth, fueled by improved diagnostics and rising awareness. The future of the market will likely be shaped by the development of more flexible treatment regimens and novel therapeutic approaches. Currently, researchers and manufacturers are striving to enhance patient convenience, with over 80 new and existing molecules being tested, including the potential for inhalation therapies. The emergence of new players and innovative treatments is expected to further expand options for patients and drive market evolution.

Competitive Landscape

Consolidated Market with Key Players Focusing on Patient Support

The market is consolidated, featuring prominent players like Grifols, S.A. and Shire plc. These leading companies are strengthening their market position through strategic initiatives such as patient support programs that build loyalty and support treatment adherence. For instance, Grifols, S.A. launched its AlfaCare program to provide comprehensive training and support for AATD patients, reinforcing the market position of its leading brand, Prolastin C.

Key Industry Development

• 2018: Grifols, S.A. launched AlfaCare, a comprehensive motivational training and support program for AATD patients, designed to strengthen the position of its leading brand, Prolastin C.

• 2016: Kamada Ltd and Shire plc received US FDA approval for an expanded label for Glassia, making it the first self-infused augmentation therapy treatment for adults with emphysema due to severe AATD.